J.P. Morgan Healthcare Conference

Colfax Corporation

Matt Trerotola, President & CEO

January 14, 2020

Forward Looking Statement & Non-GAAP Disclaimer

This presentation may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions, the impact on creditworthiness and financial viability of customers, and other impacts on Colfax's business and ability to execute business continuity plans, and the other factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as other risks discussed in Colfax's filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

The term "Colfax" in reference to the activities described in this presentation may mean one or more of Colfax's global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.

Colfax has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures may include one or more of the following: adjusted net income, adjusted net income per share, adjusted EBITA (earnings before interest, taxes and amortization), adjusted EBITDA (adjusted EBITA plus depreciation and other amortization), adjusted EBITA margin, adjusted EBITDA margin, organic sales growth, and free cash flow. Colfax also provides adjusted EBITA, adjusted EBITDA, adjusted EBITA margin and adjusted EBITDA margin on a segment basis.

- Adjusted net income from continuing operations represents net income (loss) from continuing operations excluding restructuring and other related charges, European Union Medical Device Regulation ("MDR") and other costs, debt extinguishment charges, acquisition-related amortization and other non-cash charges, and strategic transaction costs. Colfax also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations

- Adjusted net income per diluted share from continuing operations represents adjusted income from continuing operations divided by the number of adjusted diluted weighted average shares. Both GAAP and non-GAAP diluted net income per share data is computed based on weighted average shares outstanding and, if there is net income from continuing operations (rather than net loss) during the period, the dilutive impact of share equivalents outstanding during the period. Diluted weighted average shares outstanding and adjusted diluted weighted average shares outstanding are calculated on the same basis except for the net income or loss figure used in determining whether to include such dilutive impact.

- Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, acquisition-related amortization and other non-cash charges, MDR and other costs, and strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) on a segment basis, where we exclude the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income.

- Core or organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations.

- Decremental margin represents the change in Adjusted EBITA divided by the change in Net sales.

- Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment.

These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of Colfax. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that Colfax uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation.

Colfax Strategy to Create Shareholder Value

What we are

Multi-platform enterprise of market-leading businesses

What we do

Compound value by continuously improving our businesses and investing in acquisitions & innovation to build-out our platforms

Leverage our business system to drive sustainable process improvements in everything we do

Shape our portfolio to further improve organic growth and gross margins

Where we are today

FabTech platform outperforming with history of margin expansion and strong & growing cash flow

MedTech platform poised for MSD+ growth with attractive acquisition opportunities

Rebuilding momentum, constantly improving

Well-positioned for long-term value creation

Colfax Portfolio Transformation

2017-2019: Transformation

- DJO Global acquired, $1.2B revenue
- Divested Fluid Handling and Air & Gas Handling (~$2B revenue)

2020+: Diversified Tech Growth

- Grow existing businesses
- Accelerate growth with strategic acquisitions



> 90%
Sales from recurring, run-rate products
- Better growth prospects
- Less cyclical

> 90%
FCF conversion target
- More reliable, less cyclical cash flow to support strategic growth

> 45%
Gross margins with industry-defining products and brands
- Clear paths for continued margin expansion

Strong Pipeline
of M&A targets to strengthen businesses
- Improve cost / scale
- Accelerate innovation
- Expand geo & adjacent mkt access

Strong portfolio, significant opportunities for profitable growth and investment

1-Includes estimated DJO pre-acquisition sales occurring in January and February 2019; does not include Air & Gas Handling sales in the period

FabTech: Building a Great Global Leader

ESAB®

*A **global leader** in welding and cutting solutions*

2015	
Sales	$2.0B
Adj. EBITA Margin	11.5%

350+ bps of margin improvement

- ✓ **Developed innovation engine**
- ✓ **Used CBS to improve productivity**
- ✓ **Consolidated sites (47 sites to 34)**
- ✓ **Proactively managed price / costs**
- ✓ **Improved portfolio through M&A**

2019	
Sales	$2.25B
Adj. EBITA Margin	15.1%

Positioned to Resume Momentum Post COVID

- Winning with CBS, plenty of improvement headroom left
- Commercial execution and innovation delivering share gain
- Capitalizing on automation and digital solutions
- Strong and consistent cash flow supports Colfax M&A strategy

Demonstrated success of Colfax business model

Refer to Appendix for non-GAAP reconciliation and footnotes

MedTech: Strong Growth Platform

DJO® *Leading **innovator** across the **growing** orthopedic continuum of care*

2019	
Sales[1] *Organic Growth*	$1.25B *~4%*
Adj. EBITDA Margin[1] Adj. EBITA Margin[1]	~22% ~17%

Apply CBS & Strategy to:

- ✓ **Accelerate innovation process improvements**
- ✓ **Drive continuous improvement, productivity and efficiency**
- ✓ **Expand platform through M&A and connected medicine**

Future
$3B+ MedTech Platform with mid-single digit growth capabilities
Continuous margin improvement

Significant Potential for Growth

- Strong secular drivers underpin attractive market growth
- Fast-growing surgical implants business, leader in Reverse Shoulder in US
- Global leader in Bracing & Supports, strong momentum pre-COVID impact
- Many attractive acquisition vectors

Strong opportunities for growth and margin improvement

1-2019 performance includes results from January and February 2019, which were prior to the acquisition of DJO; actual results only included 10 months of DJO performance following February 22, 2019 acquisition date
Refer to Appendix for non-GAAP reconciliation and footnotes

MedTech: Uniquely Advantaged in $22B Served Market

DJO®

DJO® *Long-term **market leadership** positions & industry-defining **brands***

Bracing & Supports

Rehabilitation

Footcare

PREVENTION & REHABILITATION

Bracing & Supports ($3bn global market) — ***#1 Globally***

Rehabilitation Equipment ($1bn global market) — ***#1 Globally***

Footcare ($0.2bn US market) — ***#1 in US***

DONJOY®
DEFIANCE® CUSTOM ACL BRACE

AIRCAST®
AIRSELECT® WALKING BOOT

chattanooga®
INTELECT MOBILE 2 RPW

Surgical

BGS

RECONSTRUCTIVE

Surgical Implants ($17bn global market) — ***#1 in US Reverse Shoulder***

Bone Growth Stimulation ($0.5bn US market) — ***#2 in US***

djosurgical.
ALTIVATE® REVERSE® SHOULDER

Industry-defining brands and technology

Only End-to-End Provider Across Orthopedics Markets

Prevention ---------- Repair ---------- Recovery

PERFORMANCE	PREVENTION	SURGICAL	RECOVERY	REHAB
• Athletic braces • Muscle stimulation	• Pre-op braces • Slings • Protective solutions • Orthotic shoes	• Shoulders • Knees • Hips	• Post-op braces • Bone growth stim. • DVT • Cold therapy	• Traction devices • Electrotherapy • Heat/cold therapy

MOTIONMD®
Purpose-built SaaS platform

MotioniQ™
Connected medicine

Uniquely positioned along orthopedic continuum of care

MedTech: Key Market Positions and Opportunity

DJO

	PREVENTION & REHABILITATION
	Bracing & Rehabilitation products (~$4B global market)
Market Growth	LSD
DJO Position	Leader
DJO Growth	Market +
Competitors/ Peers	Ossur, Breg
Advantages/ Opportunities	Iconic brands, clinic workflows, continuous innovation

Returned to growth in 2H 2019, focused on growing > market:

1. Significantly improved operational execution and service levels
2. Revitalizing product vitality
3. Leveraging MotionMD and connected medicine

Improving innovation engine, accelerating pace of new products

MedTech: Key Market Positions and Opportunity (continued)

DJO®

RECONSTRUCTIVE

	Shoulder Implants (~$1B US market)	Hip/Knee (~$9B US market)
Market Growth	**MSD/HSD**	**LSD**
DJO Position	**Top Tier**	**1-2% share**
DJO Growth	**1.5X -2X market**	**3X -5X market**
Competitors/ Peers	**Stryker/Wright, Zimmer-Biomet, Exactech**	**Zimmer-Biomet, Stryker, JNJ, Smith & Nephew**
Advantages/ Opportunities	**ALTIVATE® reverse, agile innovation, planning and guidance**	**EMPOWR® Knee, agile innovation, ASC solutions, surgical workflow**

Sustaining long-term double-digit organic growth in Surgical:

1. Build on demonstrated outcome performance of Altivate Reverse® Shoulder and Empowr® Knee
2. Continue bag expansion to fill out product offering
3. Expand Shoulder franchise to "surround the doc"
4. Capitalize on ASC transition
5. Expand to key global markets

Clear path for continued strong growth

MedTech: Significant Pipeline of Acquisition Opportunities

Many Attractive Acquisition Vectors



- Proactive approach rooted in business strategy
- Clear view of value creation thesis, synergy requirements
- Intense focus on commercial diligence pre- and post-offer
- Disciplined assessment; willing to walk away
- Detailed integration plans; regular follow up / review

Strategic intent to create $3B+ MedTech platform over time

MedTech: Expansion Example – Foot/Ankle

DJO

Extremities

Shoulder Implants (~$1B US market)	Foot/Ankle Surgery (~$1B US market)	Elbow/wrist/finger (~$0.4B US market)
MSD/HSD market cagr	*MSD/HSD market cagr*	*LSD/MSD market cagr*

Other Procedures

Total ankle reconstruction market segment

STAR™ ankle: Strategic entry with leading technology and top tier share

Further opportunities to expand our MedTech business

MedTech: Adding Strategic Value to Our Medtech Platform

DJO®



LightForce® Therapy Lasers

Companion® Animal Health Products

- Acquisition of LiteCure®, the market leader in therapeutic laser technology for human and animal health
  - Annual sales of ~$25-$30 million
  - Significantly accretive to Prevention and Rehabilitation growth (HSD/LDD) and gross margins
  - Marketed under the brand names of LightForce® Therapy Lasers for humans and Companion® for animals
- Expands product portfolio into faster-growing high power laser segment
- Provides strong entry point into animal health space

Strengthens market leadership position and accelerates growth

Recent Financial Performance Highlights

- Entered 2020 with plan for growth
  - MedTech MSD and FabTech LSD revenue growth & earnings growth > 10%
  - FCF of $250mm or more and 90%+ conversion
- COVID interrupted 2020 performance but did not change our long-term momentum
  - Long-term growth drivers intact
  - 8 consecutive quarters of relative growth outperformance
- Continuing to strengthen our Company
  - Executing robust restructuring plans
  - Expect sequential earnings and cash flow improvements in Q4

Improving Financial Performance

Sales



	Q1 20	Q2 20	Q3 20
Adj. EPS	$0.38	$0.09	$0.41
Free Cash Flow	$25mm	$18mm	$49mm

Recovery momentum accelerated in Q3

Refer to Appendix for non-GAAP reconciliation and footnotes

An Exciting Future For Colfax

Current Priorities	Looking Ahead
▪ Keep associates safe and maintain supply to our customers	▪ Build a $3 billion MedTech platform with MSD+ growth capability
▪ Continue to deliver market outperformance, driven by strong commercial and innovation execution	▪ Pursue continuous improvement in operating margin across portfolio
▪ Execute on our M&A strategy; actively pursuing pipeline of strategic deals	▪ Realize strong cash conversion to support investment in the business
▪ Regain growth momentum and financial strength	▪ Diversify and strengthen portfolio through innovation & bolt-on acquisitions

Positioned to win as markets recover

Appendix

Non-GAAP Reconciliation

Colfax Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)

	Year Ended December 31, 2019			Year Ended December 31, 2015		
	Fabrication Technology			Fabrication Technology		
Net sales	$	2,247.0		$	1,985.3	
Operating income		**279.6**	**12.4%**		**170.1**	**8.6%**
Restructuring and other related charges		23.0	1.0%		29.7	1.5%
Segment operating income	**$**	**302.6**	**13.5%**	**$**	**199.8**	**10.1%**
Strategic transaction costs		-			-	
Adjusted operating profit	**$**	**302.6**	**13.5%**	**$**	**199.8**	**10.1%**
Acquisition-related amortization and other non-cash charges[1]		35.6	1.6%		29.4	1.5%
Adjusted EBITA	**$**	**338.2**	**15.1%**	**$**	**229.2**	**11.5%**

(1) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Non-GAAP Reconciliation

Colfax Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Change in Sales
Dollars in millions
(Unaudited)

	Medical Technology[1]	
	$	**%**
For the year ended December 31, 2018	$ 1,201.9	
Components of change:		
Existing businesses[2]	52.3	4.4%
Acquisitions[3]	10.7	0.9%
Foreign currency translation[4]	(15.4)	-1.3%
	47.6	4.0%
For the year ended December 31, 2019	**$ 1,249.5**	

(1) Sales and sales components include Medical Technology sales prior to the February 2019 acquisition, which are based on or derived from Management's internal reports. On the Company's form 10-K for the year ended December 31, 2019, Medical Technology Net sales include only sales subsequent to February 22, 2019, the date of the DJO acquisition, which are included in the acquisitions line item of the change in sales reconciliation.
(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.
(3) Represents the incremental sales for acquisitions completed in our Medical Technology segment.
(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

Non-GAAP Reconciliation

Colfax Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)

	Medical Technology				
	For the ten-months ended December 31, 2019			Year ended December 31, 2019 [1]	
Net sales	$	1,080.4		$	1,249.6
Segment operating income		96.2	8.9%		
Strategic transaction costs		-			
Adjusted operating profit	**$**	**96.2**	**8.9%**		
Acquisition-related amortization and other non-cash charges[2]		102.9	9.5%		
Adjusted EBITA	**$**	**199.0**	**18.4%**	**Approximately**	**17%**
Depreciation and other amortization		49.0	4.5%		
Adjusted EBITDA	**$**	**248.0**	**23.0%**	**Approximately**	**22%**

(1) Medical Technology net sales, aEBITA and aEBITDA for January and February 2019 are prior to our acquisition of DJO. The amounts are based on or derived from Management's internal reports.
(2) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Non-GAAP Reconciliation

Colfax Corporation
Reconciliation of GAAP to non-GAAP Measures
Dollars in millions, except per share amounts
(Unaudited)

	Three months ended		
	April 3, 2020	**July 3, 2020**	**October 2, 2020**
Adjusted Net Income and Adjusted Net Income Per Share			
Net income (loss) from continuing operations attributable to Colfax Corporation[(1)]	$ 7.8	$ (3.6)	$ 16.0
Restructuring and other related charges - pretax[(2)]	11.0	11.2	6.3
MDR and other - pretax[(3)]	0.9	1.0	2.6
Acquisition-related amortization and other non-cash charges - pretax[(4)]	35.8	36.1	36.2
Strategic transaction costs - pretax[(5)]	0.9	1.7	0.6
Tax adjustment[(6)]	(2.6)	(33.7)	(5.2)
Adjusted net income from continuing operations	$ 53.9	$ 12.7	$ 56.6
Adjusted net income per share - diluted from continuing operations	$ 0.38	$ 0.09	$ 0.41
Net income (loss) per share - diluted from continuing operations (GAAP)	$ 0.06	$ (0.03)	$ 0.12

(1) Net income (loss) from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income (loss) from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $1.0, $0.4 and $0.8 for the three months ended April 3, 2020, July 3, 2020 and October 2, 2020, respectively. Net loss from continuing operations attributable to Colfax Corporation for the three months ended July 3, 2020 includes a $6.8 discrete tax benefit associated with the filing of timely elected changes to U.S. Federal tax returns to credit rather than to deduct foreign taxes. The discrete benefit has been excluded from the effective tax rates used to calculate adjusted net income and adjusted net income per share.
(2) Includes $1.8, $0.9 and $2.2 of expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three months ended April 3, 2020, July 3, 2020 and October 2, 2020, respectively.
(3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017.
(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.
(5) Includes costs incurred for the acquisition of DJO.
(6) The effective tax rates used to calculate adjusted net income from continuing operations and adjusted net income from continuing operations per share were 22.3%, 21.5% and 30.1% for the three months ended April 3, 2020, July 3, 2020 and October 2, 2020, respectively.

Note: Some periods may not foot due to rounding.

Non-GAAP Reconciliation

Colfax Corporation
Reconciliation of GAAP to non-GAAP Measures
Dollars in millions
(Unaudited)

	Three months ended			Nine months ended
	April 3, 2020	**July 3, 2020**	**October 2, 2020**	**October 2, 2020**
Net cash provided by operating activities	$ 56.2	$ 37.0	$ 79.9	$ 173.1
Purchases of Property, plant and equipment	$ (31.1)	$ (19.3)	$ (31.2)	$ (81.6)
Free cash flow	**$ 25.1**	**$ 17.7**	**$ 48.8**	**$ 91.6**

Note: Some periods may not foot due to rounding.